Skip to main content

Table 3 Clinical trials based on CAR-NK cell therapy for human hematological malignancies registered in ClinicalTrials.gov (May 2021)

From: CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies

Condition Dose Target Ag Phase Participant number Location NCT number
Non-Hodgkin lymphoma (NHL) 2 × 106 /kg
6 × 106 /kg
2 × 107/kg
CD19 Early 1 9 China NCT04639739
B cell lymphoma (BCL) 50 × 103 /kg
600 × 103 /kg
CD22 Early 1 9 China NCT03692767
Non-Hodgkin lymphoma (NHL N.A CD19 1 25 China NCT04887012
B cell lymphoma (BCL) 50 × 103 /kg
600 × 103 /kg
CD19 Early 1 9 China NCT03690310
Multiple Myeloma (MM) N.A BCMA 1/2 23 China NCT03940833
B cell lymphoma (BCL) 50 × 103 /kg
600 × 103 /kg
CD19
CD22
Early 1 10 China NCT03824964
Mantle cell lymphoma (MCL)
Diffuse large B cell lymphoma (DLBCL)
Non-Hodgkin lymphoma (NHL) Follicular lymphoma (FL)
N.A CD19 1/2 0 USA NCT03579927